Tyligand Bioscience

Shanghai, China · Founded 2018 · In IPO Registration

Developer and manufacturer of oral oncology drugs and antibody-drug conjugate platforms designed for KRAS-mutated and other solid tumors. Tyligand Bioscience is based in Shanghai, China and was founded in 2018. Its last reported valuation was $222 million in Jan 2026. It has raised $111 million.

Last reported valuation
$222.2M
Oct 2026
Priced at
—
Total raised
$110.6M
Last round
—
No prints on record

No secondary trades in Tyligand Bioscience shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.

Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Tyligand Bioscience with a free account
  • ·The complete investor list: 14 names
  • ·Watch Tyligand Bioscience: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Where Tyligand Bioscience prices come from

Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Tyligand Bioscience stock.